APO Research
Talk to an analyst

APO RESEARCH · REPORT

QSOX2 Antibody

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global QSOX2 Antibody Market Outlook and Growth Opportunities 2026

19 December 2025193 pages

Choose your research edition.

Industry ResearchQSOX2 Antibody Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal QSOX2 Antibody Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal QSOX2 Antibody Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal QSOX2 Antibody Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal QSOX2 Antibody Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global QSOX2 Antibody market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for QSOX2 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for QSOX2 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for QSOX2 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the QSOX2 Antibody market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the QSOX2 Antibody market include Thermo Fisher Scientific, United States Biological, ProSci, OriGene, MBL International, LSBio, Creative Diagnostics, Bethyl and Abnova, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global QSOX2 Antibody market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of QSOX2 Antibody and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents QSOX2 Antibody revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global QSOX2 Antibody market.

QSOX2 Antibody Segment by Company

Thermo Fisher Scientific

United States Biological

ProSci

OriGene

MBL International

LSBio

Creative Diagnostics

Bethyl

Abnova

Abcam

QSOX2 Antibody Segment by Type

Polyclonal

Monoclonal

QSOX2 Antibody Segment by Application

Western Blot

Immunoprecipitation

Immunocytochemistry

Immunohistochemistry Paraffin

Others

QSOX2 Antibody Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global QSOX2 Antibody status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the QSOX2 Antibody key companies, revenue, market share, and recent developments.

3. To split the QSOX2 Antibody breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions QSOX2 Antibody market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify QSOX2 Antibody significant trends, drivers, influence factors in global and regions.

6. To analyze QSOX2 Antibody competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global QSOX2 Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of QSOX2 Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of QSOX2 Antibody.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global QSOX2 Antibody industry.

Chapter 3: Detailed analysis of QSOX2 Antibody company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of QSOX2 Antibody in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of QSOX2 Antibody in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. QSOX2 Antibody Industry Trends Table 2. QSOX2 Antibody Industry Drivers Table 3. QSOX2 Antibody Industry Opportunities and Challenges Table 4. QSOX2 Antibody Industry Restraints Table 5. Global QSOX2 Antibody Revenue by Company (US$ Million) & (2021-2026) Table 6. Global QSOX2 Antibody Revenue Share by Company (2021-2026) Table 7. Global QSOX2 Antibody Company Ranking, (2024-2026) & (US$ Million) Table 8. Global QSOX2 Antibody Key Company Manufacturing Base & Headquarters Table 9. Global QSOX2 Antibody Company, Product Type & Application Table 10. Global QSOX2 Antibody Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global QSOX2 Antibody by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Polyclonal Table 15. Significant Companies of Monoclonal Table 16. Global QSOX2 Antibody Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global QSOX2 Antibody Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global QSOX2 Antibody Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global QSOX2 Antibody Sales Value Share by Type (2021-2026) Table 20. Global QSOX2 Antibody Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Western Blot Table 22. Significant Companies of Immunoprecipitation Table 23. Significant Companies of Immunocytochemistry Table 24. Significant Companies of Immunohistochemistry Paraffin Table 25. Significant Companies of Others Table 26. Global QSOX2 Antibody Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global QSOX2 Antibody Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global QSOX2 Antibody Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global QSOX2 Antibody Sales Value Share by Application (2021-2026) Table 30. Global QSOX2 Antibody Sales Value Share by Application (2027-2032) Table 31. Global QSOX2 Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global QSOX2 Antibody Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global QSOX2 Antibody Sales Value Share by Region (2021-2026) Table 34. Global QSOX2 Antibody Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global QSOX2 Antibody Sales Value Share by Region (2027-2032) Table 36. Global QSOX2 Antibody Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global QSOX2 Antibody Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global QSOX2 Antibody Sales Value Market Share by Country (2021-2026) Table 39. Global QSOX2 Antibody Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global QSOX2 Antibody Sales Value Market Share by Country (2027-2032) Table 41. Thermo Fisher Scientific Company Information Table 42. Thermo Fisher Scientific Business Overview Table 43. Thermo Fisher Scientific QSOX2 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Thermo Fisher Scientific QSOX2 Antibody Product Portfolio Table 45. Thermo Fisher Scientific Recent Development Table 46. United States Biological Company Information Table 47. United States Biological Business Overview Table 48. United States Biological QSOX2 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. United States Biological QSOX2 Antibody Product Portfolio Table 50. United States Biological Recent Development Table 51. ProSci Company Information Table 52. ProSci Business Overview Table 53. ProSci QSOX2 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. ProSci QSOX2 Antibody Product Portfolio Table 55. ProSci Recent Development Table 56. OriGene Company Information Table 57. OriGene Business Overview Table 58. OriGene QSOX2 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. OriGene QSOX2 Antibody Product Portfolio Table 60. OriGene Recent Development Table 61. MBL International Company Information Table 62. MBL International Business Overview Table 63. MBL International QSOX2 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. MBL International QSOX2 Antibody Product Portfolio Table 65. MBL International Recent Development Table 66. LSBio Company Information Table 67. LSBio Business Overview Table 68. LSBio QSOX2 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. LSBio QSOX2 Antibody Product Portfolio Table 70. LSBio Recent Development Table 71. Creative Diagnostics Company Information Table 72. Creative Diagnostics Business Overview Table 73. Creative Diagnostics QSOX2 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Creative Diagnostics QSOX2 Antibody Product Portfolio Table 75. Creative Diagnostics Recent Development Table 76. Bethyl Company Information Table 77. Bethyl Business Overview Table 78. Bethyl QSOX2 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Bethyl QSOX2 Antibody Product Portfolio Table 80. Bethyl Recent Development Table 81. Abnova Company Information Table 82. Abnova Business Overview Table 83. Abnova QSOX2 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Abnova QSOX2 Antibody Product Portfolio Table 85. Abnova Recent Development Table 86. Abcam Company Information Table 87. Abcam Business Overview Table 88. Abcam QSOX2 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Abcam QSOX2 Antibody Product Portfolio Table 90. Abcam Recent Development Table 91. Research Programs/Design for This Report Table 92. Authors List of This Report Table 93. Secondary Sources Table 94. Primary Sources List of Figures Figure 1. QSOX2 Antibody Product Image Figure 2. Global QSOX2 Antibody Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global QSOX2 Antibody Market Size (2021-2032) & (US$ Million) Figure 4. Global QSOX2 Antibody Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Polyclonal Image Figure 8. Monoclonal Image Figure 9. Global QSOX2 Antibody Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global QSOX2 Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global QSOX2 Antibody Sales Value Share by Type (2021-2032) Figure 12. Western Blot Image Figure 13. Immunoprecipitation Image Figure 14. Immunocytochemistry Image Figure 15. Immunohistochemistry Paraffin Image Figure 16. Others Image Figure 17. Global QSOX2 Antibody Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global QSOX2 Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global QSOX2 Antibody Sales Value Share by Application (2021-2032) Figure 20. Global QSOX2 Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global QSOX2 Antibody Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America QSOX2 Antibody Sales Value (2021-2032) & (US$ Million) Figure 23. North America QSOX2 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe QSOX2 Antibody Sales Value (2021-2032) & (US$ Million) Figure 25. Europe QSOX2 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific QSOX2 Antibody Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific QSOX2 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America QSOX2 Antibody Sales Value (2021-2032) & (US$ Million) Figure 29. South America QSOX2 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa QSOX2 Antibody Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa QSOX2 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA QSOX2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada QSOX2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico QSOX2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany QSOX2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France QSOX2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. QSOX2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy QSOX2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain QSOX2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia QSOX2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands QSOX2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries QSOX2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China QSOX2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan QSOX2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea QSOX2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India QSOX2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia QSOX2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia QSOX2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil QSOX2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina QSOX2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile QSOX2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia QSOX2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru QSOX2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia QSOX2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel QSOX2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE QSOX2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey QSOX2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran QSOX2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt QSOX2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Polyclonal
  • Monoclonal
Applications
  • Western Blot
  • Immunoprecipitation
  • Immunocytochemistry
  • Immunohistochemistry Paraffin
  • Others
Companies covered
  • Thermo Fisher Scientific
  • United States Biological
  • ProSci
  • OriGene
  • MBL International
  • LSBio
  • Creative Diagnostics
  • Bethyl
  • Abnova
  • Abcam

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global QSOX2 Antibody Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global QSOX2 Antibody Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 QSOX2 Antibody Market Dynamics
  1. 2.1 QSOX2 Antibody Industry Trends
  2. 2.2 QSOX2 Antibody Industry Drivers
  3. 2.3 QSOX2 Antibody Industry Opportunities and Challenges
  4. 2.4 QSOX2 Antibody Industry Restraints
3 QSOX2 Antibody Market by Company
  1. 3.1 Global QSOX2 Antibody Company Revenue Ranking in 2025
  2. 3.2 Global QSOX2 Antibody Revenue by Company (2021-2026)
  3. 3.3 Global QSOX2 Antibody Company Ranking (2024-2026)
  4. 3.4 Global QSOX2 Antibody Company Manufacturing Base and Headquarters
  5. 3.5 Global QSOX2 Antibody Company Product Type and Application
  6. 3.6 Global QSOX2 Antibody Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global QSOX2 Antibody Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 QSOX2 Antibody Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 QSOX2 Antibody Market by Type
  1. 4.1 QSOX2 Antibody Type Introduction
  2. 4.1.1 Polyclonal
  3. 4.1.2 Monoclonal
  4. 4.2 Global QSOX2 Antibody Sales Value by Type
  5. 4.2.1 Global QSOX2 Antibody Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global QSOX2 Antibody Sales Value by Type (2021-2032)
  7. 4.2.3 Global QSOX2 Antibody Sales Value Share by Type (2021-2032)
5 QSOX2 Antibody Market by Application
  1. 5.1 QSOX2 Antibody Application Introduction
  2. 5.1.1 Western Blot
  3. 5.1.2 Immunoprecipitation
  4. 5.1.3 Immunocytochemistry
  5. 5.1.4 Immunohistochemistry Paraffin
  6. 5.1.5 Others
  7. 5.2 Global QSOX2 Antibody Sales Value by Application
  8. 5.2.1 Global QSOX2 Antibody Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global QSOX2 Antibody Sales Value by Application (2021-2032)
  10. 5.2.3 Global QSOX2 Antibody Sales Value Share by Application (2021-2032)
6 QSOX2 Antibody Regional Value Analysis
  1. 6.1 Global QSOX2 Antibody Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global QSOX2 Antibody Sales Value by Region (2021-2032)
  3. 6.2.1 Global QSOX2 Antibody Sales Value by Region: 2021-2026
  4. 6.2.2 Global QSOX2 Antibody Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America QSOX2 Antibody Sales Value (2021-2032)
  7. 6.3.2 North America QSOX2 Antibody Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe QSOX2 Antibody Sales Value (2021-2032)
  10. 6.4.2 Europe QSOX2 Antibody Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific QSOX2 Antibody Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific QSOX2 Antibody Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America QSOX2 Antibody Sales Value (2021-2032)
  16. 6.6.2 South America QSOX2 Antibody Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa QSOX2 Antibody Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa QSOX2 Antibody Sales Value Share by Country, 2025 VS 2032
7 QSOX2 Antibody Country-level Value Analysis
  1. 7.1 Global QSOX2 Antibody Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global QSOX2 Antibody Sales Value by Country (2021-2032)
  3. 7.2.1 Global QSOX2 Antibody Sales Value by Country (2021-2026)
  4. 7.2.2 Global QSOX2 Antibody Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA QSOX2 Antibody Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada QSOX2 Antibody Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico QSOX2 Antibody Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany QSOX2 Antibody Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France QSOX2 Antibody Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. QSOX2 Antibody Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy QSOX2 Antibody Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain QSOX2 Antibody Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia QSOX2 Antibody Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands QSOX2 Antibody Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries QSOX2 Antibody Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China QSOX2 Antibody Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan QSOX2 Antibody Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea QSOX2 Antibody Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India QSOX2 Antibody Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia QSOX2 Antibody Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia QSOX2 Antibody Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil QSOX2 Antibody Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina QSOX2 Antibody Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile QSOX2 Antibody Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia QSOX2 Antibody Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru QSOX2 Antibody Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia QSOX2 Antibody Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel QSOX2 Antibody Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE QSOX2 Antibody Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey QSOX2 Antibody Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran QSOX2 Antibody Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt QSOX2 Antibody Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt QSOX2 Antibody Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt QSOX2 Antibody Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Thermo Fisher Scientific
  2. 8.1.1 Thermo Fisher Scientific Company Information
  3. 8.1.2 Thermo Fisher Scientific Business Overview
  4. 8.1.3 Thermo Fisher Scientific QSOX2 Antibody Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Thermo Fisher Scientific QSOX2 Antibody Product Portfolio
  6. 8.1.5 Thermo Fisher Scientific Recent Developments
  7. 8.2 United States Biological
  8. 8.2.1 United States Biological Company Information
  9. 8.2.2 United States Biological Business Overview
  10. 8.2.3 United States Biological QSOX2 Antibody Revenue and Gross Margin (2021-2026)
  11. 8.2.4 United States Biological QSOX2 Antibody Product Portfolio
  12. 8.2.5 United States Biological Recent Developments
  13. 8.3 ProSci
  14. 8.3.1 ProSci Company Information
  15. 8.3.2 ProSci Business Overview
  16. 8.3.3 ProSci QSOX2 Antibody Revenue and Gross Margin (2021-2026)
  17. 8.3.4 ProSci QSOX2 Antibody Product Portfolio
  18. 8.3.5 ProSci Recent Developments
  19. 8.4 OriGene
  20. 8.4.1 OriGene Company Information
  21. 8.4.2 OriGene Business Overview
  22. 8.4.3 OriGene QSOX2 Antibody Revenue and Gross Margin (2021-2026)
  23. 8.4.4 OriGene QSOX2 Antibody Product Portfolio
  24. 8.4.5 OriGene Recent Developments
  25. 8.5 MBL International
  26. 8.5.1 MBL International Company Information
  27. 8.5.2 MBL International Business Overview
  28. 8.5.3 MBL International QSOX2 Antibody Revenue and Gross Margin (2021-2026)
  29. 8.5.4 MBL International QSOX2 Antibody Product Portfolio
  30. 8.5.5 MBL International Recent Developments
  31. 8.6 LSBio
  32. 8.6.1 LSBio Company Information
  33. 8.6.2 LSBio Business Overview
  34. 8.6.3 LSBio QSOX2 Antibody Revenue and Gross Margin (2021-2026)
  35. 8.6.4 LSBio QSOX2 Antibody Product Portfolio
  36. 8.6.5 LSBio Recent Developments
  37. 8.7 Creative Diagnostics
  38. 8.7.1 Creative Diagnostics Company Information
  39. 8.7.2 Creative Diagnostics Business Overview
  40. 8.7.3 Creative Diagnostics QSOX2 Antibody Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Creative Diagnostics QSOX2 Antibody Product Portfolio
  42. 8.7.5 Creative Diagnostics Recent Developments
  43. 8.8 Bethyl
  44. 8.8.1 Bethyl Company Information
  45. 8.8.2 Bethyl Business Overview
  46. 8.8.3 Bethyl QSOX2 Antibody Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Bethyl QSOX2 Antibody Product Portfolio
  48. 8.8.5 Bethyl Recent Developments
  49. 8.9 Abnova
  50. 8.9.1 Abnova Company Information
  51. 8.9.2 Abnova Business Overview
  52. 8.9.3 Abnova QSOX2 Antibody Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Abnova QSOX2 Antibody Product Portfolio
  54. 8.9.5 Abnova Recent Developments
  55. 8.10 Abcam
  56. 8.10.1 Abcam Company Information
  57. 8.10.2 Abcam Business Overview
  58. 8.10.3 Abcam QSOX2 Antibody Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Abcam QSOX2 Antibody Product Portfolio
  60. 8.10.5 Abcam Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst